Ildong Holdings Co Ltd Asset Resilience Ratio
Ildong Holdings Co Ltd asset resilience ratio. Ildong Holdings Co Ltd (000230) has an Asset Resilience Ratio of 1.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000230 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ildong Holdings Co Ltd (1999–2025)
Asset resilience ratio of Ildong Holdings Co Ltd from 1999 to 2025. This chart shows how Ildong Holdings Co Ltd's Asset Resilience Ratio has changed over time. Read 000230 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ildong Holdings Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ildong Holdings Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩9.09 Billion | 1.15% |
| Total Liquid Assets | ₩9.09 Billion | 1.15% |
Asset Resilience Insights
- Limited Liquidity: Ildong Holdings Co Ltd maintains only 1.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ildong Holdings Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ildong Holdings Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ildong Holdings Co Ltd Asset Resilience Ratio by Year (1999–2025)
Ildong Holdings Co Ltd asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Ildong Holdings Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.15% | ₩1.20 Billion ≈ $814.19K |
₩802.86 Billion ≈ $544.09 Million |
-1.64pp |
| 2024-12-31 | 1.79% | ₩15.28 Billion ≈ $10.35 Million |
₩854.70 Billion ≈ $579.22 Million |
-1.78pp |
| 2023-12-31 | 3.57% | ₩31.29 Billion ≈ $21.21 Million |
₩877.00 Billion ≈ $594.33 Million |
-0.77pp |
| 2022-12-31 | 4.34% | ₩37.42 Billion ≈ $25.36 Million |
₩862.55 Billion ≈ $584.54 Million |
+1.49pp |
| 2021-12-31 | 2.84% | ₩26.19 Billion ≈ $17.75 Million |
₩920.76 Billion ≈ $623.99 Million |
+2.21pp |
| 2020-12-31 | 0.64% | ₩5.09 Billion ≈ $3.45 Million |
₩799.40 Billion ≈ $541.74 Million |
+0.23pp |
| 2019-12-31 | 0.41% | ₩3.30 Billion ≈ $2.23 Million |
₩805.63 Billion ≈ $545.96 Million |
-1.28pp |
| 2018-12-31 | 1.69% | ₩4.49 Billion ≈ $3.04 Million |
₩265.47 Billion ≈ $179.90 Million |
+0.75pp |
| 2017-12-31 | 0.94% | ₩2.59 Billion ≈ $1.76 Million |
₩274.84 Billion ≈ $186.25 Million |
-1.55pp |
| 2016-12-31 | 2.49% | ₩5.09 Billion ≈ $3.45 Million |
₩204.09 Billion ≈ $138.31 Million |
+1.93pp |
| 2015-12-31 | 0.56% | ₩3.98 Billion ≈ $2.69 Million |
₩705.64 Billion ≈ $478.20 Million |
+0.16pp |
| 2014-12-31 | 0.40% | ₩2.48 Billion ≈ $1.68 Million |
₩620.35 Billion ≈ $420.40 Million |
-0.03pp |
| 2013-12-31 | 0.43% | ₩2.68 Billion ≈ $1.82 Million |
₩628.21 Billion ≈ $425.73 Million |
-0.19pp |
| 2012-12-31 | 0.62% | ₩3.35 Billion ≈ $2.27 Million |
₩541.71 Billion ≈ $367.11 Million |
-0.43pp |
| 2011-12-31 | 1.05% | ₩5.35 Billion ≈ $3.63 Million |
₩511.65 Billion ≈ $346.74 Million |
-2.64pp |
| 2010-12-31 | 3.68% | ₩19.57 Billion ≈ $13.27 Million |
₩531.23 Billion ≈ $360.01 Million |
+2.68pp |
| 2009-12-31 | 1.00% | ₩4.96 Billion ≈ $3.36 Million |
₩495.53 Billion ≈ $335.82 Million |
-0.34pp |
| 2008-12-31 | 1.34% | ₩5.43 Billion ≈ $3.68 Million |
₩404.79 Billion ≈ $274.32 Million |
+0.48pp |
| 2007-12-31 | 0.86% | ₩2.90 Billion ≈ $1.96 Million |
₩336.03 Billion ≈ $227.73 Million |
-0.07pp |
| 2006-12-31 | 0.93% | ₩2.64 Billion ≈ $1.79 Million |
₩283.77 Billion ≈ $192.31 Million |
+0.57pp |
| 2005-12-31 | 0.36% | ₩941.26 Million ≈ $637.88K |
₩258.07 Billion ≈ $174.89 Million |
-0.09pp |
| 2004-12-31 | 0.45% | ₩1.05 Billion ≈ $709.94K |
₩232.19 Billion ≈ $157.35 Million |
-0.30pp |
| 2003-12-31 | 0.75% | ₩1.65 Billion ≈ $1.12 Million |
₩218.82 Billion ≈ $148.29 Million |
+0.20pp |
| 2002-12-31 | 0.56% | ₩1.09 Billion ≈ $741.62K |
₩195.90 Billion ≈ $132.76 Million |
-0.14pp |
| 2001-12-31 | 0.70% | ₩1.27 Billion ≈ $863.51K |
₩183.11 Billion ≈ $124.09 Million |
-0.21pp |
| 2000-12-31 | 0.91% | ₩1.70 Billion ≈ $1.15 Million |
₩187.75 Billion ≈ $127.23 Million |
+0.78pp |
| 1999-12-31 | 0.12% | ₩234.02 Million ≈ $158.59K |
₩188.81 Billion ≈ $127.96 Million |
-- |
About Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the… Read more